Selected research
Industry Research
Combined Hormonal Contraceptive Industry Research Report 2026
Market perspective
The global Combined Hormonal Contraceptive market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Combined Hormonal Contraceptive is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Combined Hormonal Contraceptive is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Combined Hormonal Contraceptive is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Combined Hormonal Contraceptive include Teva Pharmaceutical Industries, Johnson & Johnson, Novartis International, Pfizer, GlaxoSmithKline, Bayer HealthCare Pharmaceuticals, Watson Pharma, Cipla and Actavis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Combined Hormonal Contraceptive market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Combined Hormonal Contraceptive Market by Company
Teva Pharmaceutical Industries
Johnson & Johnson
Novartis International
Pfizer
GlaxoSmithKline
Bayer HealthCare Pharmaceuticals
Watson Pharma
Cipla
Actavis
Combined Hormonal Contraceptive Segment by Type
Ring
Patch
Pills
Combined Hormonal Contraceptive Segment by Application
E-commerce
Retail Pharmacies
Hospital Pharmacies
Others
Combined Hormonal Contraceptive Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Combined Hormonal Contraceptive market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Combined Hormonal Contraceptive and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Combined Hormonal Contraceptive.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Combined Hormonal Contraceptive manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Combined Hormonal Contraceptive by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Combined Hormonal Contraceptive in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Ring
- Patch
- Pills
Applications
- E-commerce
- Retail Pharmacies
- Hospital Pharmacies
- Others
Companies covered
- Teva Pharmaceutical Industries
- Johnson & Johnson
- Novartis International
- Pfizer
- GlaxoSmithKline
- Bayer HealthCare Pharmaceuticals
- Watson Pharma
- Cipla
- Actavis
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Combined Hormonal Contraceptive Market Size (2021-2032)
- 2.2.2 Global Combined Hormonal Contraceptive Sales (2021-2032)
- 2.2.3 Global Combined Hormonal Contraceptive Market Average Price (2021-2032)
- 2.3 Combined Hormonal Contraceptive by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Ring
- 2.3.3 Patch
- 2.3.4 Pills
- 2.4 Combined Hormonal Contraceptive by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 E-commerce
- 2.4.3 Retail Pharmacies
- 2.4.4 Hospital Pharmacies
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Combined Hormonal Contraceptive Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Combined Hormonal Contraceptive Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Combined Hormonal Contraceptive Revenue of Manufacturers (2021-2026)
- 3.4 Global Combined Hormonal Contraceptive Average Price by Manufacturers (2021-2026)
- 3.5 Global Combined Hormonal Contraceptive Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Combined Hormonal Contraceptive, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Combined Hormonal Contraceptive, Product Type & Application
- 3.8 Global Manufacturers of Combined Hormonal Contraceptive, Established Date
- 3.9 Global Combined Hormonal Contraceptive Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva Pharmaceutical Industries
- 4.1.1 Teva Pharmaceutical Industries Company Information
- 4.1.2 Teva Pharmaceutical Industries Business Overview
- 4.1.3 Teva Pharmaceutical Industries Combined Hormonal Contraceptive Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Pharmaceutical Industries Combined Hormonal Contraceptive Product Portfolio
- 4.1.5 Teva Pharmaceutical Industries Recent Developments
- 4.2 Johnson & Johnson
- 4.2.1 Johnson & Johnson Company Information
- 4.2.2 Johnson & Johnson Business Overview
- 4.2.3 Johnson & Johnson Combined Hormonal Contraceptive Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Johnson & Johnson Combined Hormonal Contraceptive Product Portfolio
- 4.2.5 Johnson & Johnson Recent Developments
- 4.3 Novartis International
- 4.3.1 Novartis International Company Information
- 4.3.2 Novartis International Business Overview
- 4.3.3 Novartis International Combined Hormonal Contraceptive Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novartis International Combined Hormonal Contraceptive Product Portfolio
- 4.3.5 Novartis International Recent Developments
- 4.4 Pfizer
- 4.4.1 Pfizer Company Information
- 4.4.2 Pfizer Business Overview
- 4.4.3 Pfizer Combined Hormonal Contraceptive Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Pfizer Combined Hormonal Contraceptive Product Portfolio
- 4.4.5 Pfizer Recent Developments
- 4.5 GlaxoSmithKline
- 4.5.1 GlaxoSmithKline Company Information
- 4.5.2 GlaxoSmithKline Business Overview
- 4.5.3 GlaxoSmithKline Combined Hormonal Contraceptive Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 GlaxoSmithKline Combined Hormonal Contraceptive Product Portfolio
- 4.5.5 GlaxoSmithKline Recent Developments
- 4.6 Bayer HealthCare Pharmaceuticals
- 4.6.1 Bayer HealthCare Pharmaceuticals Company Information
- 4.6.2 Bayer HealthCare Pharmaceuticals Business Overview
- 4.6.3 Bayer HealthCare Pharmaceuticals Combined Hormonal Contraceptive Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Bayer HealthCare Pharmaceuticals Combined Hormonal Contraceptive Product Portfolio
- 4.6.5 Bayer HealthCare Pharmaceuticals Recent Developments
- 4.7 Watson Pharma
- 4.7.1 Watson Pharma Company Information
- 4.7.2 Watson Pharma Business Overview
- 4.7.3 Watson Pharma Combined Hormonal Contraceptive Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Watson Pharma Combined Hormonal Contraceptive Product Portfolio
- 4.7.5 Watson Pharma Recent Developments
- 4.8 Cipla
- 4.8.1 Cipla Company Information
- 4.8.2 Cipla Business Overview
- 4.8.3 Cipla Combined Hormonal Contraceptive Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Cipla Combined Hormonal Contraceptive Product Portfolio
- 4.8.5 Cipla Recent Developments
- 4.9 Actavis
- 4.9.1 Actavis Company Information
- 4.9.2 Actavis Business Overview
- 4.9.3 Actavis Combined Hormonal Contraceptive Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Actavis Combined Hormonal Contraceptive Product Portfolio
- 4.9.5 Actavis Recent Developments
5 Global Combined Hormonal Contraceptive Market Scenario by Region
- 5.1 Global Combined Hormonal Contraceptive Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Combined Hormonal Contraceptive Sales by Region: 2021-2032
- 5.2.1 Global Combined Hormonal Contraceptive Sales by Region: 2021-2026
- 5.2.2 Global Combined Hormonal Contraceptive Sales by Region: 2027-2032
- 5.3 Global Combined Hormonal Contraceptive Revenue by Region: 2021-2032
- 5.3.1 Global Combined Hormonal Contraceptive Revenue by Region: 2021-2026
- 5.3.2 Global Combined Hormonal Contraceptive Revenue by Region: 2027-2032
- 5.4 North America Combined Hormonal Contraceptive Market Facts & Figures by Country
- 5.4.1 North America Combined Hormonal Contraceptive Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Combined Hormonal Contraceptive Sales by Country (2021-2032)
- 5.4.3 North America Combined Hormonal Contraceptive Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Combined Hormonal Contraceptive Market Facts & Figures by Country
- 5.5.1 Europe Combined Hormonal Contraceptive Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Combined Hormonal Contraceptive Sales by Country (2021-2032)
- 5.5.3 Europe Combined Hormonal Contraceptive Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Combined Hormonal Contraceptive Market Facts & Figures by Country
- 5.6.1 Asia Pacific Combined Hormonal Contraceptive Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Combined Hormonal Contraceptive Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Combined Hormonal Contraceptive Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Combined Hormonal Contraceptive Market Facts & Figures by Country
- 5.7.1 South America Combined Hormonal Contraceptive Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Combined Hormonal Contraceptive Sales by Country (2021-2032)
- 5.7.3 South America Combined Hormonal Contraceptive Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Combined Hormonal Contraceptive Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Combined Hormonal Contraceptive Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Combined Hormonal Contraceptive Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Combined Hormonal Contraceptive Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Combined Hormonal Contraceptive Sales by Type (2021-2032)
- 6.1.1 Global Combined Hormonal Contraceptive Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Combined Hormonal Contraceptive Sales Market Share by Type (2021-2032)
- 6.2 Global Combined Hormonal Contraceptive Revenue by Type (2021-2032)
- 6.2.1 Global Combined Hormonal Contraceptive Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Combined Hormonal Contraceptive Revenue Market Share by Type (2021-2032)
- 6.3 Global Combined Hormonal Contraceptive Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Combined Hormonal Contraceptive Sales by Application (2021-2032)
- 7.1.1 Global Combined Hormonal Contraceptive Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Combined Hormonal Contraceptive Sales Market Share by Application (2021-2032)
- 7.2 Global Combined Hormonal Contraceptive Revenue by Application (2021-2032)
- 7.2.1 Global Combined Hormonal Contraceptive Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Combined Hormonal Contraceptive Revenue Market Share by Application (2021-2032)
- 7.3 Global Combined Hormonal Contraceptive Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Combined Hormonal Contraceptive Value Chain Analysis
- 8.1.1 Combined Hormonal Contraceptive Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Combined Hormonal Contraceptive Production Mode & Process
- 8.2 Combined Hormonal Contraceptive Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Combined Hormonal Contraceptive Distributors
- 8.2.3 Combined Hormonal Contraceptive Customers
9 Global Combined Hormonal Contraceptive Analyzing Market Dynamics
- 9.1 Combined Hormonal Contraceptive Industry Trends
- 9.2 Combined Hormonal Contraceptive Industry Drivers
- 9.3 Combined Hormonal Contraceptive Industry Opportunities and Challenges
- 9.4 Combined Hormonal Contraceptive Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst